Neogenomics INC

NeoGenomics announced second-quarter 2026 results with an 11% year-over-year revenue increase to $202 million, driven by robust clinical services and NGS growth, leading to raised full-year guidance.

NeoGenomics has finalized a civil settlement with the U.S. Department of Justice, agreeing to pay $9,813,260 to resolve an investigation into consulting services provided to healthcare providers.

NeoGenomics has finalized a civil settlement with the Department of Justice, agreeing to pay $9,813,260 to resolve an investigation into consulting services provided to healthcare providers.

NeoGenomics has expanded its Board of Directors to ten members with the appointment of former Flatiron Health CEO Carolyn Starrett.

NeoGenomics announced the pricing of a $275 million offering of convertible senior notes due 2032 to qualified institutional buyers, alongside a concurrent repurchase of existing notes.

NeoGenomics has initiated a private offering of $275 million in convertible senior notes due 2032 to fund debt repurchases and share buybacks.

NeoGenomics, Inc. announced its financial results for the second quarter ended June 30, 2026, showing an 11.2% increase in revenue and a return to net income.

NeoGenomics reports an 11.1% revenue increase to $186.7 million for Q1 2026, driven by higher test volumes and strategic initiatives.

NeoGenomics reported an 11.9% revenue increase in Q3 2025, reaching $187.8 million, but saw its net loss widen to $27.1 million due to significant impairment charges and higher operating costs.

NeoGenomics, Inc. reported a 10.2% increase in Q2 2025 revenue to $181.3 million, driven by test volume and strategic reimbursement initiatives, but saw its net loss widen significantly to $45.1 million due to substantial impairment charges from the planned sale of Trapelo Health and the wind-down of InVisionFirst-Lung.

NeoGenomics reports a 7.5% increase in revenue for Q1 2025, driven by higher test volume and average unit price, while completing its restructuring program.

NeoGenomics' Q3 2024 results show a revenue increase driven by Clinical Services, while Advanced Diagnostics experienced a slight decline.

NeoGenomics' 2024 annual report highlights a revenue increase of 11.6% and significant improvements in profitability.

NeoGenomics, Inc. saw a 16% increase in consolidated revenue in 2023, primarily driven by an 18.4% growth in its Clinical Services segment.

Carolyn S. Starrett, a Director at NEOGENOMICS INC, reported the acquisition of stock options and restricted stock units on June 23, 2026.

Director Lynn A. Tetrault of Neogenomics Inc. has reported transactions involving common stock and stock options, indicating a shift in beneficial ownership.

Neogenomics Inc. Director Lynn Tetrault reported a transaction involving the acquisition of 5,307 shares of common stock.

Director John P. Kenny acquired 5,893 shares of NeoGenomics common stock through the vesting of restricted stock units.

Director Felicia Williams exercised restricted stock units and received new equity grants in NeoGenomics Inc.

Director Lynn Tetrault acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.

NeoGenomics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on May 21, 2026, to elect directors, approve executive compensation, amend its equity incentive plan, and ratify its accounting firm.

NeoGenomics, Inc. has filed a definitive proxy statement with the SEC.

NeoGenomics is asking stockholders to approve an amendment to its 2023 Equity Incentive Plan to increase the share reserve, establish minimum vesting periods, and prohibit liberal share recycling.

NeoGenomics, Inc. has filed a definitive proxy statement with the SEC.

NeoGenomics has scheduled its 2024 Annual Meeting of Stockholders for May 23, 2024, featuring proposals on director elections, executive compensation, an employee stock purchase plan amendment, and auditor ratification.

BlackRock, Inc. has reported a beneficial ownership of 20,358,331 shares, representing 15.6% of the common stock of NeoGenomics Inc., as of June 30, 2026.

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, reporting beneficial ownership of 10,113,261 shares, representing 7.77% of NeoGenomics, Inc. common stock.

Greenhouse Funds LLLP and associated parties have filed an amendment reporting a 7.1% beneficial ownership stake in NeoGenomics, Inc.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G reporting a 1.7% beneficial ownership stake in NeoGenomics, Inc.

First Light Asset Management, LLC and Mathew P. Arens have jointly filed a Schedule 13G, reporting beneficial ownership of over 10% of Neogenomics, Inc. common stock as of April 30, 2026.

Vanguard Capital Management reports beneficial ownership of over 6.6 million shares, representing 5.09% of NeoGenomics Inc.'s common stock as of March 31, 2026.